Search hospitals > Iowa > Boone
McFarland Clinic - Boone
Claim this profileBoone, Iowa 50036
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Melanoma
Conducts research for Tumors
112 reported clinical trials
1 medical researcher
Summary
McFarland Clinic - Boone is a medical facility located in Boone, Iowa. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Melanoma, Tumors and other specialties. McFarland Clinic - Boone is involved with conducting 112 clinical trials across 300 conditions. There are 1 research doctors associated with this hospital, such as Joseph J. Merchant.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Clinical Trials running at McFarland Clinic - Boone
Breast Cancer
Bladder Cancer
Melanoma
Cancer
Lung Cancer
Renal Cell Carcinoma
Bladder Carcinoma
Cutaneous Melanoma
Squamous Cell Carcinoma
Gastroesophageal Junction Adenocarcinoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at McFarland Clinic - Boone?
McFarland Clinic - Boone is a medical facility located in Boone, Iowa. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Melanoma, Tumors and other specialties. McFarland Clinic - Boone is involved with conducting 112 clinical trials across 300 conditions. There are 1 research doctors associated with this hospital, such as Joseph J. Merchant.